Protective effect of vaccination against mumps complications, Czech Republic, 2007-2012

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F16%3A00011283" target="_blank" >RIV/75010330:_____/16:00011283 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/16:43911203

Výsledek na webu

<a href="http://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-016-2958-4" target="_blank" >http://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-016-2958-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12889-016-2958-4" target="_blank" >10.1186/s12889-016-2958-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Protective effect of vaccination against mumps complications, Czech Republic, 2007-2012

Popis výsledku v původním jazyce

In the Czech Republic, two-dose immunization against mumps achieves 98 % coverage. The routine reporting detects mumps cases, clinical complications, and hospital admissions in unvaccinated but also in vaccinated individuals. Using surveillance data of patients with mumps we assessed the effectiveness of mumps vaccination on mumps clinical complications and hospitalization need. We also investigated the effect of the time since immunization. We analysed data on incident mumps cases reported to the Czech national surveillance system in 2007-2012. Results: From total of 9663 mumps analysed cases 5600 (58 %) occurred in males. The mean age at the disease onset was 17.3, median 16 years. Ninety percent of the study patients had no complications, while 1.6 % developed meningitis, 0.2 % encephalitis, and 0.6 % pancreatitis. Mumps orchitis occurred in 659 (11.8 %) male cases. In total, 1192 (12.3 %) patients required hospitalization. Two doses of vaccine received by 81.8 % cases significantly reduced the risk of hospitalization. This study demonstrates a significant preventive effect of two-dose vaccination against mumps complications (orchitis, meningitis, or encephalitis) and hospitalization for mumps. The risk of complications increases with time interval from vaccination. Teenagers and young adults were the most affected age groups.

Název v anglickém jazyce

Protective effect of vaccination against mumps complications, Czech Republic, 2007-2012

Popis výsledku anglicky

In the Czech Republic, two-dose immunization against mumps achieves 98 % coverage. The routine reporting detects mumps cases, clinical complications, and hospital admissions in unvaccinated but also in vaccinated individuals. Using surveillance data of patients with mumps we assessed the effectiveness of mumps vaccination on mumps clinical complications and hospitalization need. We also investigated the effect of the time since immunization. We analysed data on incident mumps cases reported to the Czech national surveillance system in 2007-2012. Results: From total of 9663 mumps analysed cases 5600 (58 %) occurred in males. The mean age at the disease onset was 17.3, median 16 years. Ninety percent of the study patients had no complications, while 1.6 % developed meningitis, 0.2 % encephalitis, and 0.6 % pancreatitis. Mumps orchitis occurred in 659 (11.8 %) male cases. In total, 1192 (12.3 %) patients required hospitalization. Two doses of vaccine received by 81.8 % cases significantly reduced the risk of hospitalization. This study demonstrates a significant preventive effect of two-dose vaccination against mumps complications (orchitis, meningitis, or encephalitis) and hospitalization for mumps. The risk of complications increases with time interval from vaccination. Teenagers and young adults were the most affected age groups.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT14059" target="_blank" >NT14059: Klinicky manifestní příušnice v očkované populaci - genotypizace původce a sérologický profil pacienta.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BMC Public Health

ISSN

1471-2458

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

April

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

—

Kód UT WoS článku

000373257600002

EID výsledku v databázi Scopus

—